Aseptic Filling for Gene Therapies and Next-Generation Biologics Within Closed Robotic Workcells

This webcast features: Thomas Page, PhD, Vice President, Engineering and Asset Development, FUJIFILM Diosynth Biotechnologies

Fujifilm Diosynth Biotechnologies (FDB) sought to “close the loop” by keeping all upstream and downstream aseptic processing operations within closed systems. The missing part was downstream, where FDB implemented a closed robotic filling workcell for manufacturing gene therapies.

Workcells solve long-standing problems with sterility assurance, containment, and process control in aseptic filling. The knowledge developed by FDB during its implementation and early use of a closed workcell can benefit organizations developing new drug products.

Participants will learn about the following topics:

– Transitioning to a fully closed, robotically driven aseptic filling process

– Removing humans from the process for “touchless” filling

– Managing hazard pathways and risks to drug products

– Ensuring “closure by design” for product safety and vial integrity

Watch the recorded webcast below.